Where you live matters: Regional differences in healthcare resource use for psoriasis in the United States.
It is unknown which U.S. census region offers best access to healthcare resources. To compare healthcare resource use and costs for psoriasis patients among the four U.S. census regions. Cross-sectional study using the 1996-2015 Medical Expenditure Panel Survey. In the U.S., the greatest access for biologics was in the South (9.1% receiving biologics/year), followed by Northeast (7.4%), West (6.8%), and Midwest (5.2%). Ambulatory visits per patient per year (PPPY) were highest in the West (5.02), followed by Northeast (3.81), South (2.95), and Midwest (2.84). The proportion of patients with ≥1 emergency department (ED) visits was highest in the Northeast (2.73%), followed by West (2.17%), South (1.19%), and Midwest (1.17%). Compared to the remainder of the country, the West incurred the lowest total healthcare costs (p=0.035) and the lowest drug costs (p=0.023). While South had the greatest proportion of patients on biologics (9.1% vs 6.4%, p=0.045), it also had 30% fewer ambulatory visits PPPY and 39% lower proportion of ED visits for psoriasis. Psoriasis severity was unavailable. Southern U.S. states have the greatest access to biologics and incurred fewer ambulatory and ED visits. The Midwest had lowest access to biologics and ambulatory and ED care.